Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F16%3A00065361" target="_blank" >RIV/00159816:_____/16:00065361 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00090788

Výsledek na webu

<a href="http://dx.doi.org/10.1155/2016/4087632" target="_blank" >http://dx.doi.org/10.1155/2016/4087632</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2016/4087632" target="_blank" >10.1155/2016/4087632</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment

Popis výsledku v původním jazyce

Inflammatory cardiomyopathy is defined as inflammation of the heart muscle associated with impaired function of the myocardium. In our region, its etiology is most often viral. Viral infection is a possible trigger of immune and autoimmune mechanisms which contributed to the damage of myocardial function. Myocarditis is considered the most common cause of dilated cardiomyopathy. Typical manifestation of this disease is heart failure, chest pain, or arrhythmias. The most important noninvasive diagnostic method is magnetic resonance imaging, but the gold standard of diagnostics is invasive examination, endomyocardial biopsy. In a significant proportion of cases with impaired left ventricular systolic function, recovery occurs spontaneously in several weeks and therefore it is appropriate to postpone critical therapeutic decisions about 3-6 months after start of the treatment. Therapy is based on standard heart failure treatment; immunosuppressive or antimicrobial treatment may be considered in some cases depending on the results of endomyocardial biopsy. If severe dysfunction of the left ventricle persists, device therapy may be needed.

Název v anglickém jazyce

Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment

Popis výsledku anglicky

Inflammatory cardiomyopathy is defined as inflammation of the heart muscle associated with impaired function of the myocardium. In our region, its etiology is most often viral. Viral infection is a possible trigger of immune and autoimmune mechanisms which contributed to the damage of myocardial function. Myocarditis is considered the most common cause of dilated cardiomyopathy. Typical manifestation of this disease is heart failure, chest pain, or arrhythmias. The most important noninvasive diagnostic method is magnetic resonance imaging, but the gold standard of diagnostics is invasive examination, endomyocardial biopsy. In a significant proportion of cases with impaired left ventricular systolic function, recovery occurs spontaneously in several weeks and therefore it is appropriate to postpone critical therapeutic decisions about 3-6 months after start of the treatment. Therapy is based on standard heart failure treatment; immunosuppressive or antimicrobial treatment may be considered in some cases depending on the results of endomyocardial biopsy. If severe dysfunction of the left ventricle persists, device therapy may be needed.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BioMed Research International

ISSN

2314-6133

e-ISSN

—

Svazek periodika

2016

Číslo periodika v rámci svazku

2016

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

4087632

Kód UT WoS článku

000378704900001

EID výsledku v databázi Scopus

—